-
The primary care physician who cares for couples in their childbearing years should encourage women and their partners to receive preconception care. The physician can enhance this opportunity by adopting a preconception focus during annual medical exams and asking the patients about their conception plans.
-
FDA Approves Generic Version of AstraZenecas Prilosec; Pegasys
Approved To Treat Hepatitis C; HRT Reduces Alzheimers Risk, Study
Says; Heparin Plus Alteplase More Effective; Digoxin Effects Differ By
Sex; McClellan Named FDA Commissioner; FDA Actions
-
Vitamin-Mineral Supplementation and Acute RTI in Elderly; B-Type
Natriuretic Peptide Levels and Outcome in Heart Failure; Companion
Influence During Primary Care Encounters; Handrubbing with
Alcohol-Based Solution vs. Standard Handwashing; Program To Prevent
Functional Decline in Frail Elderly Who Live at Home; Treatment of
Diabetic Neuropathy with Isosorbide Dinitrate Spray
-
A seizure is an abnormal, hypersynchronous discharge of a population of cortical neurons that may be associated with clinical manifestations corresponding to the area of the brain involved. Epilepsy is a disorder of the central nervous system in which symptoms are 2 or more seizures greater than 24 hours apart, not provoked by another cause.
-
Fibrates and statins are associated with a 42-fold and 8-fold increased risk of myopathy, respectively, compared to normal controls, but the incidence remains low, at 6 per 100,000 and 1 per 100,000, respectively.
-
Considerable concern exists among clinicians regarding the risk-benefit ratio of long-term anticoagulation compared to antiplatelet treatment. In order to compare the risk of vascular events and bleeding complications in patients with AF, van Walraven and associates analyzed data from 6 randomized clinical trials.
-
Three recent studies have provided epidemiologic data that increased intake of antioxidants may be associated with a reduced risk of developing AD.
-
In this thoughtful, well-balanced review, Clarke and Guttman review the evidence for using new dopamine agonists to treat patients with early PD.
-
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
